IP Library Granted Patent US 7,951,791
Granted Patent B2
US 7,951,791 · App. 12/046,599 · Granted May 31, 2011

Amino-substituted tricyclic derivatives and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,951,791
App. No.
12/046,599
Granted
May 31, 2011
Kind
B2
Abstract

Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y 1 and Y 2 form various tricyclic cores, X a and X b are C, CH, or N, as defined herein, and R x is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands that encompass compounds of formula (I) and other tricyclic derivatives. Methods of using amino-substituted tricyclic derivatives also are described herein.

Claims (27)

1. A compound of the formula (I):

or a pharmaceutically acceptable salt or amide thereof, wherein:

A and/or B are

a group of formula (g):

X a and X b are each independently C(H);

Y 1 is S, S(O), or S(O) 2 ;

Y 2 is a bond;

R x is independently selected at each occurrence from the group consisting of halogen, alkoxy, amino, alkylamino, dialkylamino, acylamino, dialkylaminoalkyl, and cyano;

a is 0 or 1;

b is 0 or 1; provided that when one of a and b is 0, the other is 1; and

ab is 2 or 3, and cd is 1 or 2.

2. The compound according to claim 1 , wherein the group of formula (g) is selected from the group consisting of:

and enantiomers thereof.

3. The compound according to claim 1 , selected from the group consisting of:

3,7-bis[(3S)-1-azabicyclo[2.2.2]octan-3-yloxy]-dibenzothiophene;

2-[(1S,5S)-3,6-diazabicyclo[3.2.0]heptan-3-yl]-dibenzothiophene-5,5-dioxide;

3,7-bis[3,7-diazabicyclo[3.3.0]octan-3-yl]-dibenzothiophene-5,5-dioxide;

3,7-bis[7-methyl-3,7-diazabicyclo[3.3.0]octan-3-yl]-dibenzothiophene-5,5-dioxide;

3-[3,7-diazabicyclo[3.3.0]octan-3-yl]-dibenzothiophene-5,5-dioxide;

3-[7-methyl-3,7-diazabicyclo[3.3.0]octan-3-yl]-dibenzothiophene-5,5-dioxide;

3-amino-7-[3,7-diazabicyclo[3.3.0]octan-3-yl]-dibenzothiophene-5,5-dioxide;

2,7-bis-[3,7-diazabicyclo[3.3.0]octan-3-yl]-dibenzothiophene-5,5-dioxide;

1-(5,5-dioxo-5H-5λ 6 -dibenzothiophen-3-yl)-4-methylpiperazine;

(1S,5S)-3-(5,5-dioxo-5H-5λ 6 -dibenzothiophen-3-yl)-3,6-diazabicyclo[3.2.0]heptane;

(1S,5S)-3-(5,5-dioxo-5H-5λ 6 -dibenzothiophen-3-yl)-6-methyl-3,6-diazabicyclo[3.2.0]heptane; and

4-(5,5-dioxo-5H-5λ 6 -dibenzothiophen-3-yl)-1,4-diazabicyclo[3.2.2]nonane.

4. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030182/0547 →